Evidence map›Paper›PMID 37768503›Full record

ReviewMolecular biotechnology2024

Peptide-Based Therapeutics in Cancer Therapy.

Abduladheem Turki Jalil, Mohanad Ali Abdulhadi, Lubna R Al-Ameer, Waam Mohammed Taher, Sada Jasim Abdulameer, Munther Abosaooda, Ali A Fadhil

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Toxicology reports · 2025
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abduladheem Turki JalilDepartment of Medical Laboratories Techniques, Al-Mustaqbal University College, Hilla, Babylon, 51001, Iraq. abedalazeem799@gmail.com.ORCID http://orcid.org/0000-0001-8403-7465
Mohanad Ali AbdulhadiDepartment of Medical Laboratory Techniques, Al-Maarif University College, Al-Anbar, Iraq.
Lubna R Al-AmeerCollege of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq.
Waam Mohammed TaherNational University of Science and Technology, Dhi Qar, Iraq.
Sada Jasim AbdulameerBiology Department, College of Education for Pure Science, Wasit University, Kut, Wasit, Iraq.
Munther AbosaoodaCollege of Pharmacy, the Islamic University, 54001, Najaf, Iraq.
Ali A FadhilMedical Technical College, Al-Farahidi University, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A monster called cancer is still one of the most challenging human problems and one of the leading causes of death in the world. Different types of treatment methods are used for cancer therapy; however, there are challenges such as high cost and harmful side effects in using these methods. Recent years have witnessed a surge in the development of therapeutic peptides for a wide range of diseases, notably cancer. Peptides are preferred over antibiotics, radiation therapy, and chemotherapy in the treatment of cancer due to a number of aspects, including flexibility, easy modification, low immunogenicity, and inexpensive cost of production. The use of therapeutic peptides in cancer treatment is a novel and intriguing strategy. These peptides provide excellent prospects for targeted drug delivery because of their high selectivity, specificity, small dimensions, good biocompatibility, and simplicity of modification. Target specificity and minimal toxicity are benefits of therapeutic peptides. Additionally, peptides can be used to design antigens or adjuvants for vaccine development. Here, types of therapeutic peptides for cancer therapy will be discussed, such as peptide-based cancer vaccines and tumor-targeting peptides (TTP) and cell-penetrating peptides (CPP).

Indexed as

Cancer VaccinesCell-Penetrating PeptidesNeoplasmsAnimalsAntineoplastic AgentsDrug Delivery SystemsHumansPeptidesAntineoplastic AgentsCancer VaccinesCell-Penetrating PeptidesPeptidesCancerDrug deliveryPeptide VaccineTherapeutic peptides

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.